Company AnnouncementAugust 21, 2026

Life science commercialization

Kaironexus launches commercialization firm for life-science tools and medical devices

The founder-led company will help technical teams move from product strategy through launch, partnerships, manufacturing, and commercial scale.

25+Life-science launches
$150M+Client capital raised
30K+Industry contacts and KOLs

SAN JOSE, Calif. Kaironexus has launched a commercialization firm built for technical founders and leadership teams developing life-science tools, diagnostics, biotechnology products, and medical devices.

The company is designed to operate as the commercial team an early-stage technical organization may not yet be ready to build internally. Its work spans market and corporate strategy, launch planning, licensing and partnership development, manufacturing, supply-chain readiness, and global distribution.

Built for the gap between invention and adoption

Scientific teams can spend years proving that an instrument or platform works, then encounter a different set of constraints when it is time to define the buyer, establish pricing, prepare the field organization, scale production, or enter a new market. Kaironexus brings those workstreams together under one founder-led team.

The company brings experience from more than 25 life-science product launches and a network of more than 30,000 scientists, key opinion leaders, and industry contacts.

IntelliCyt$90M

Cash acquisition by Sartorius after the iQue platform reached the top 15 global pharmaceutical companies.

ThinkCyte9 months

VisionSort moved from design to manufacturing release, followed by more than $5 million in first-year revenue.

ForteBio$42.3M

Raised across Series A through C to launch Octet and build an 11-product biosensor portfolio.

“Strategy without execution is a slide. We are here for what comes after the deck.”The Kaironexus team

Four connected commercial workstreams

  • Strategy and corporate advisory

    Market definition, buyer strategy, commercial models, and milestone planning.
  • Commercial strategy and launch support

    Launch planning, pricing, reimbursement, channel strategy, and field readiness.
  • Licensing and partnerships

    Partner identification, evaluation, negotiation, and collaboration development.
  • Manufacturing and supply chain

    CMO and CDMO selection, scale-up readiness, and distribution relationships across the Americas, Europe, and Asia.

Founder-led from strategy through execution

Kaironexus is led by CEO Janette Phi, MBA; co-founder and Chief Commercial Officer Brett Gordon; and Business Development Director Nick Wilson, MBA.

Janette Phi, MBA

Janette Phi, MBA

Chief Executive Officer

Strategy, commercialization, and capital across pharma and life-science tool launches.

Brett Gordon

Brett Gordon

Chief Commercial Officer

Operations, manufacturing, and global distribution through launch and scale.

Nick Wilson, MBA

Nick Wilson, MBA

Business Development Director

Licensing, partnerships, and business development across biotech and diagnostics.

Companies preparing a first launch, building early commercial traction, expanding into new regions, or strengthening their manufacturing and partnership strategy can learn more at kaironexus.bio.

Kaironexus is a commercialization firm serving life-science tools, diagnostics, biotech, and medical-device companies. The team works with technical founders and C-level leaders from pre-seed through Series B on strategy, launches, partnerships, manufacturing, supply chains, and distribution.

About this announcement

This announcement was supplied by or prepared for Kaironexus. Company descriptions, experience figures, and quotations are attributable to Kaironexus. Device Pulse announcements are published separately from independent reviews, comparisons, rankings, and buyer-research conclusions.